This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PEG-Interferon beta 1a

Nektar Therapeutics

Drug Names(s): PEG-Interferon beta 1a

Description: Serono partnered with Nektar to create a novel Advanced PEGylation technique toPEGylate its interferon beta molecule. After assessing the protein’s structure, Nektar, working with Serono, developed a novelPEGylation strategy to first PEGylate an inaccessible cysteine within the molecule with alow molecular weight, thiol-specific PEG specially synthesized for the purpose. It wasthen possible to attach a high molecular weight PEG to the remaining functional groupon the low molecular weight PEG.

Deal Structure: In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business with the former Merck KGaA Ethicals Division was completed. Merck Serono is now the division of Merck KGaA which specializes in prescription pharmaceuticals. Its North American business operates in the United States and Canada under EMD Serono.

Partners: Merck KGaA


PEG-Interferon beta 1a News

Pink Sheet Interferon labeling


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug